# OnCo record hcc-advanced (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hcc-advanced/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hcc-advanced" ;
  schema:name "Advanced hepatocellular carcinoma (BCLC C)"@en ;
  schema:alternateName "Advanced-stage HCC"@en, "Unresectable hepatocellular carcinoma"@en, "Metastatic hepatocellular carcinoma"@en, "HCC with portal vein invasion"@en, "BCLC C"@en ;
  schema:description "Advanced hepatocellular carcinoma has invaded the liver's veins or spread beyond it. Sorafenib was the only drug for a decade; now the combination of the immunotherapy atezolizumab with the anti-angiogenic antibody bevacizumab, or the two-antibody regimen durvalumab with tremelimumab, is standard first line, and several further drugs follow it."@en ;
  schema:url <https://onco.cc/cancers/hcc-advanced/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hepatocellular_carcinoma> ;
  schema:citation <https://www.nejm.org/doi/full/10.1056/NEJMoa0708857>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1915745>, <https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070>, <https://en.wikipedia.org/wiki/Hepatocellular_carcinoma> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/trials/checkmate-9dw/>, <https://onco.cc/drugs/camrelizumab-rivoceranib/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/livmoniplimab/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/targets/gpc3/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/cabozantinib/> ;
  onco:standardOfCare <https://onco.cc/trials/imbrave150/>, <https://onco.cc/trials/himalaya/>, <https://onco.cc/trials/checkmate-9dw/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/terms/child-pugh/>, <https://onco.cc/trials/reflect/>, <https://onco.cc/trials/sharp/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/trials/resorce/>, <https://onco.cc/trials/celestial/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/terms/afp/>, <https://onco.cc/terms/portal-vein-tumour-thrombus/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/radioembolisation-tare/>, <https://onco.cc/terms/hbv-hcv/>, <https://onco.cc/terms/child-pugh/> .